-
-
-
-
-
-
-
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002 Program
-
-
-
-
-
-
-
Form S-3 CAPRICOR THERAPEUTICS,
-
-
-
-
-
-
-
Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
-
-
-
-
-
-
-
Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
-
-
-
-
-
-
-
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Capricor Therapeutics to Participate in Upcoming Conferences
-
70,527 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

